Clinical Trial Update: HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluating hypomethylating agents plus donor lymphocyte infusion versus donor lymphocyte infusion preemptive therapy guided by minima…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Minimal Residual Disease

Drugs mentioned

• Donor Lymphocyte Infusion
• Hypomethylating agents

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation | Phase 2, Phase 3 | Status: UNKNOWN